Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe

Trial Profile

Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Daclatasvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms CMPASS-EU
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 03 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 02 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.
    • 02 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top